ライフサイエンスコーパス: osimertinib

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 e mechanisms developed in patients receiving osimertinib.

2 om all patients in the first-in-man study of osimertinib.

3 of outcome from a third-generation EGFR-TKI, osimertinib.

4 or assessed as possibly treatment-related to osimertinib.

5 ed tyrosine kinase inhibitors, nilotinib and osimertinib.

6 y or the AKT pathway enhanced the effects of osimertinib.

7 R tyrosine-kinase inhibitor therapy received osimertinib 80 mg orally once daily; treatment could con

8 GFR Thr790Met mutation who were treated with osimertinib, a third-generation EGFR TKI, after previous

9 l patients who received at least one dose of osimertinib and had measurable disease at baseline accor

10 ich were overcome by combined treatment with osimertinib and SFK inhibitors.

11 FR tyrosine kinase inhibitors (TKI), such as osimertinib, are active agents for the treatment of EGFR

12 Osimertinib (AZD9291) is an oral, potent, irreversible E

13 Therefore, osimertinib could be a suitable treatment for patients w

14 essed in all patients receiving at least one osimertinib dose (full analysis set).

15 n of several covalent drugs (e.g., afatinib, osimertinib, ibrutinib, neratinib, and CC-292).

16 ht dictate future development strategies for osimertinib in clinical trials.

17 We assessed the efficacy and safety of osimertinib in patients with EGFR Thr790Met-positive non

18 Osimertinib is approved for the treatment of non-small-c

19 inase inhibitor therapy, and T790M mutation, osimertinib is recommended; if NSCLC lacks the T790M mut

20 Patients took 20-240 mg osimertinib per day until disease progression or develop

21 Median overall survival after osimertinib progression was 5.4 months (95% CI 4.1-10.0)

22 inhibitors with high activities against the osimertinib resistant L858R/T790M/C797S mutant.

23 SFK family member YES1 was amplified in osimertinib-resistant EGFR-mutant tumor cells, the effec

24 ignaling under continuous EGFR inhibition in osimertinib-sensitive cells.

25 Osimertinib showed clinical activity with manageable sid

26 itive for T790M in plasma have outcomes with osimertinib that are equivalent to patients positive by

27 patients were screened, of whom 210 started osimertinib treatment between June 13, 2014, and Oct 27,

28 rises in approximately 33% of patients after osimertinib treatment, occurs in <3% after rociletinib.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。